Abbott Laboratories (ABT) Depreciation & Amortization (CF) (2009 - 2026)

Abbott Laboratories has reported Depreciation & Amortization (CF) for 18 years, with the latest figure at $402.0 million in Q2 2026.

• Quarterly Depreciation & Amortization (CF) rose 12.61% year-over-year to $402.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.5 billion (up 11.57% YoY) and the FY2025 annual result came in at $1.4 billion, up 7.01% from the prior year.
• Depreciation & Amortization (CF) grew to $402.0 million in Q2 2026 per ABT's latest filing, from $381.0 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $402.0 million in Q2 2026 and troughed at $302.0 million in Q2 2023.
• A 5-year average of $338.2 million and a median of $332.5 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2026: Depreciation & Amortization (CF) declined 26.82% in 2022, then increased 13.39% in 2026.
• Over 5 years, Depreciation & Amortization (CF) stood at $311.0 million in 2022, then grew by 6.75% to $332.0 million in 2023, then advanced by 3.01% to $342.0 million in 2024, then grew by 8.19% to $370.0 million in 2025, then advanced by 8.65% to $402.0 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $402.0 million, $381.0 million, and $370.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.